AACR Virtual Meeting: Precision Medicine Strategies to Improve Therapy of Diffuse Large B-Cell Lymphoma (DLBCL)
September 30–October 1, 2021
Louis M. Staudt, National Cancer Institute, Bethesda, Massachusetts
Ranjana H. Advani, Stanford Cancer Institute, Stanford, California
Georg Lenz, University of Münster, Münster, Germany
Wyndham H. Wilson, National Cancer Institute, Bethesda, Maryland
Lymphomas represent a remarkably heterogeneous set of cancers that have traditionally been subdivided histologically. As a result, treatments have been developed for each histological category of lymphoma irrespective of molecular differences among the tumors in each category. The advent of high-throughput sequencing of tumor genomes, exomes, and transcriptomes has revealed remarkable genetic and phenotypic heterogeneity within each lymphoma histological category. Current therapies for lymphoma work well for some patients and fail others, which has been traced to differences in the molecular features of lymphomas. Clinical trials have largely not kept pace with the rapidly expanding knowledge of lymphoma genetic subtypes and of specific genetic aberrations that promote their malignant behavior. This AACR Virtual Meeting will focus specifically on diffuse large B-cell lymphoma (DLBCL) and will convene experts in lymphoma genetics, drug development, and clinical trials who will explore the current landscape of treatment, the rational development of new therapeutic regimens, and the design of precision medicine trials in the future.